has established itself as a useful management strategy for men with testosterone deficiency (TD). While CC has been shown to be efficacious in younger men and men with low baseline luteinizing hormone (LH) levels, it is unclear if it is effective in a diverse population of TD patients. We attempted to develop a nomogram to aid clinicians in defining the likelihood of response to CC in men with TD.
INTRODUCTION AND OBJECTIVES: Clomiphene citrate (CC)
has established itself as a useful management strategy for men with testosterone deficiency (TD). While CC has been shown to be efficacious in younger men and men with low baseline luteinizing hormone (LH) levels, it is unclear if it is effective in a diverse population of TD patients. We attempted to develop a nomogram to aid clinicians in defining the likelihood of response to CC in men with TD.
METHODS: The study population included all men on CC for TD who had available information on age, and baseline and posttreatment T and LH levels. Men with baseline total T ! 400 ng/dL were excluded. All men started on 25mg clomiphene every other day (QOD) and those with only a partial response were increased to 50mg QOD. Descriptive statistics were used to describe the patient cohort. Logistic regression was used to model the probability of attaining a total T increase of 200 ng/dL within 6 months. Predictors entered into the model were patient age, baseline total T, and baseline LH levels (see figure below) .
RESULTS: A total of 143 men in our database had the appropriate data and were included in our study. Median age was 61.7 (IQR 50, 67.5) years. Median baseline T was 287 (IQR 220, 327) ng/dL and LH 3.65 (2.8, 4.9) IU/L. For comorbidities, 42% of men had hypertension, 14.7% diabetes, 45.5% hyperlipidemia, 21.7% sleep apnea, 2.8% coronary artery disease. 32% men were on 25mg QOD and 68% were increased to 50mg QOD. 62% of men had an increase in T of !200ng/dL within 6 months of starting CC. Predictors of achieving this T increase were younger age, lower baseline LH, and lower baseline total T, though none of these were found statistically significant at a 0.05 level. The concordance index for the nomogram was 0.54. Functional examples of the performance of the nomogram are presented in the table below.
CONCLUSIONS: 62% of men experience a T increase of ! 200ng/dL within 6 months of starting CC. The most potentially influential predictor of this rise is patient age, followed by baseline total T and then baseline LH.
Source of Funding: None

MP58-06 ASSESSMENT OF ERYTHROCYTOSIS FOLLOWING LONG-ACTING TESTOSTERONE SUPPLEMENTATION
INTRODUCTION AND OBJECTIVES: Testosterone supplementation is known to stimulate erythropoiesis and can lead to erythrocytosis, which may be associated with adverse cardiovascular events. The mechanism by which erythrocytosis occurs is multifactorial, but long-acting formulations are believed to be associated with a lower risk of erythrocytosis compared to short-acting injections. We evaluated the available long-acting formulations of testosterone, subcutaneous testosterone pellets (TP) and testosterone undecanoate (TU), and their comparative risk of erythrocytosis.
METHODS: A retrospective review of 127 patients treated with TP or TU for hypogonadism (total testosterone < 300 ng/dL) over a 5-year period was conducted. Men with hematopoietic disorders were excluded. Testosterone (T), free testosterone (FT), estradiol (E2), PSA, hemoglobin (Hgb), and hematocrit (Hct) were evaluated. Descriptive statistics (Pearson chi-square and t-test) and multivariate logistic regression were performed to evaluate variables associated with erythrocytosis, defined by Hct > 50%.
RESULTS: Of 127 men reviewed, 79 received TP and 48 received TU. Baseline characteristics were similar between the groups, including age, BMI, and proportion of patients with diabetes, hypertension, hyperlipidemia, or history of cardiovascular disease. Pretreatment mean total T (TP 188 ng/dL, TU 214 ng/dL, p [ 0.063), FT (TP 38 ng/dL, TU 36 ng/dL, p [ 0.60), PSA (TP 1.54 ng/mL, TU 1.70 ng/mL, p [ 0.59), Hgb (TP 14.8 g/dL, TU 14.9 g/dL, p [ 0.80), and Hct (TP 43.6%, TU 42.5%, p [ 0.23) were similar between groups. Post-treatment T levels were higher in the TP group (mean T: TP 658 ng/dL, TU 530 ng/dL, p [ < 0.01; mean peak T: TP 1039 ng/dL, TU 665 ng/dL, p < 0.01). Mean peak E2 levels were higher in the TP group (TP 59.7 pg/mL, TU 36.8 pg/mL, p < 0.01). Men on TP had a higher Hct (TP 48.6%, TU 46.4%, p < 0.01) and rate of erythrocytosis (TP 36.7%, TU 18.8%, p [ 0.03) . Longer duration on therapy was observed in the TP group (TP 40.1 mo., TU 18.5 mo., p [ < 0.01) but no significant difference in the time to erythrocytosis (TP 13.1 mo., TU 7.4 mo., p [ 0.11) was observed. On multivariate analysis, only pre-treatment hemoglobin was independently associated with increased risk of erythrocytosis (OR 1.92, 95% CI 1.24 -2.98, p < 0.01).
CONCLUSIONS: Erythrocytosis following long-acting testosterone supplementation was observed more often in men receiving TP with higher mean and peak T levels. The most important factor associated with erythrocytosis appears to be baseline hemoglobin concentration. Patients at risk for erythrocytosis may be more appropriate candidates for TU.
